A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

@article{Biederman2006ARP,
  title={A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.},
  author={Joseph Biederman and Eric O. Mick and Craig B H Surman and Robert O. Doyle and Paul G Hammerness and Theresa Harpold and Stephanie B Dunkel and Meghan Dougherty and Megan Aleardi and Thomas Spencer},
  journal={Biological psychiatry},
  year={2006},
  volume={59 9},
  pages={829-35}
}
BACKGROUND The objective of this study was to evaluate the safety and efficacy of once-daily OROS methylphenidate (MPH) in the treatment of adults with DSM-IV attention-deficit/hyperactivity disorder (ADHD). METHODS We conducted a randomized, 6-week, placebo-controlled, parallel-design study of OROS MPH in 141 adult subjects with DSM-IV ADHD, using standardized instruments for diagnosis. OROS MPH or placebo was initiated at 36 mg/day and titrated to optimal response, depending on efficacy and… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 88 extracted citations

Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry • 2013
View 6 Excerpts
Highly Influenced

Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD

The international journal of neuropsychopharmacology • 2012
View 9 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…